Bortezomib attenuates murine collagen-induced arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 11, 2009, Pages 1761-1767

  Lee, S W ^a   Kim, J H ^a   Park, Y B ^a   Lee, S K ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; COLLAGEN TYPE 2; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; AUTACOID; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DBA 1 MOUSE; DRUG DOSE COMPARISON; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; JOINT DESTRUCTION; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; ANIMAL; DBA MOUSE; DOSE RESPONSE; DRUG SCREENING; HOSPITALIZATION; METABOLISM; METHODOLOGY; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED DBA; PROTEASE INHIBITORS; PYRAZINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; X-RAY MICROTOMOGRAPHY;

EID: 70449727070     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.097709     Document Type: Article

References (19)

1. Ciechanover A, Orian A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: mode of action and clinical implications. J Cell Biochem Suppl 2000;34:40-51.
2. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-1534 (Pubitemid 36182530)
3. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006;20:1341-1352 (Pubitemid 44084044)
4. Hochberg MC, Silman AJ, Smolen JS, et al. Rheumatology. London, UK: Mosby, 871-872
5. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071 (Pubitemid 27163860)
6. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916 (Pubitemid 32224400)
7. Lee JS, Cho ML, Jhun JY, et al. Antigen-specific expansion of TCR Vbeta3+ CD4+ T cells in the early stage of collagen-induced arthritis and its arthritogenic role in DBA/ 1J mice. J Clin Immunol 2006;26:204-212
8. Cho ML, Kang JW, Moon YM, et al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL- 1 receptor antagonist-deficient mice. J Immunol 2006;176:5652-5661
9. Waarsing JH, Day JS, Weinans H. An improved segmentation method for in vivo microCT imaging. J Bone Miner Res 2004;19:1640-1650 (Pubitemid 41094327)
10. Müller R, Hildebrand T, Rüegsegger P. Non-invasive bone biopsy: a new method to analyse and display the three-dimensional structure of trabecular bone. Phys Med Biol 1994;39:145-164 (Pubitemid 24063705)
11. Guilak F. Volume and surface area measurement of viable chondrocytes in situ using geometric modelling of serial confocal sections. J Microsc 1994;173:245-256
12. Laib A, Hildebrand T, Häuselmann HJ, Rüegsegger P. Ridge number density: a new parameter for in vivo bone structure analysis. Bone 1997;21:541-546 (Pubitemid 28029698)
13. Aggarwal BB. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB. Ann Rheum Dis 2000;59(Suppl 1):i6-16.
14. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997;100:2417-2423
15. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001;2:907-916
16. Vila-Del Sol V, Fresno M. Involvement of TNF and NF-(kappa)B in the transcriptional control of cyclooxygenase-2 expression by IFN-(gamma) in macrophages. J Immunol 2005;174:2825-2833 (Pubitemid 40279699)
17. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
18. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498 (Pubitemid 41007864)
19. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873